Xencor, Inc. (Xencor) is a clinical-stage biopharmaceutical company. The Company focused on discovering and developing engineered monoclonal antibodies to treat severe and life-threatening diseases with unmet medical needs. The Company uses its XmAb technology platform to create antibody product candidates designed to treat autoimmune and allergic diseases, cancer and other conditions. The Company pipeline includes XmAb5871, XmAb7195 and XmAb5574/MOR208. XmAb5871 is being developed for the treatment of autoimmune diseases, including rheumatoid arthritis and lupus. XmAb7195 is being developed for the treatment of severe asthma and allergic diseases. XmAb5574/MOR208 is being developed for the treatment of blood-based cancers and uses our Cytotoxic Fc Domain.